BITE

Welcome to the Brand page for “BITE”, which is offered here for [ medicaments, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host diseases, transplant rejection, coronary heart diseases, and minimal residual diseases, in the form of intravenous, sub-cutaneous, intra-peritoneal, intra-muscular and aerosol therapies ];color is not claimed as a feature of the mark.;[ human and veterinary services, licensing of medicaments, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases, and minimal residual diseases; licensing of technology for the identification of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases, and minimal residual diseases, and for the identification of expressed genes, particularly of abnormal expressed genes, for the analysis and identification of the gene expression pattern and eukaryotic cells, particularly of single cells and cell culture lines, particularly of mammalian and human cells, particularly of cells of microscopic small biopsies of animal and human tissues, of cells out of tissue samples prepared with laser, of cells isolated with facs or with receptor to ligand binding, of chemical fixed tissue, of micrometastatic cells, of bone marrow cells, of samples of body fluids, particularly from liquor, blood, lymph, urine or bowel movement, of stem cells, cloned single cells or differentiated stages from specific cells ];medical services; laboratory research in the field of polypeptides, particularly antibodies and antibody derivatives; human and veterinary services, product development, in the field of medicaments, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases and minimal residual diseases; product development, in the field of diagnostic and testing apparatus and instruments for the identification of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host diseases, transplant rejection, coronary heart diseases, and minimal residual diseases, and for the identification of expressed genes, particularly of abnormal expressed genes, for the analysis and identification of the gene expression pattern and eukaryotic cells, particularly of single cells and cell culture lines, particularly of mammalian and human cells, particularly of cells of microscopic small biopsies of animal and human tissues, of cells out of tissue samples prepared with laser, of cells isolated with facs or with receptor to ligand binding, of chemical fixed tissue, of micrometastatic cells, of bone marrow cells, of samples of body fluids, particularly from liquor, blood, lymph, urine or bowel movement, of stem cells, cloned single cells or differentiated stages from specific cells;.

Its status is currently believed to be active. Its class is unavailable. “BITE” is believed to be currently owned by “AMGEN RESEARCH (MUNICH) GMBH”.